Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sleep cycle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Sleep cycle. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-005475-40 Sponsor Protocol Number: VP-VEC-162-3502 Start Date*: 2022-06-08
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)
    Medical condition: Delayed Sleep-Wake Phase Disorder (DSWPD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10041013 Sleep-wake schedule disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004520-35 Sponsor Protocol Number: VP-VEC-162-3204 Start Date*: 2012-12-06
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: AN EXTENSION OPEN-LABEL SAFETY STUDY OF A 24-MONTH 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION WHO ...
    Medical condition: Blind males or females with no conscious light perception and the complaint of a sleep-wake disorder associated with Non-24 Hour Sleep- Wake Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10009191 Circadian rhythm sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000281-35 Sponsor Protocol Number: VP-VEC-162-3201 Start Date*: 2011-06-09
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon versus Placebo in Totally Blind Subjects with N24HSWD followed...
    Medical condition: Blind males or females with no conscious light perception and the complaint of a sleep-wake disorder associated with Non-24 Hour Sleep-Wake Disorder.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10009191 Circadian rhythm sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001357-40 Sponsor Protocol Number: HDZNRW-KA_006_TB Start Date*: 2016-11-08
    Sponsor Name:Klinik für Kardiologie, Herz- und Diabeteszentrum NRW
    Full Title: High-Flow-Therapy for the treatment of Cheyne-Stokes-Respiration in chronic heart failure: A randomized, controlled, cross-over trial
    Medical condition: Cheyne-Stokes Respiration in chronic heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020912-12 Sponsor Protocol Number: VP-VEC-162-3202 Start Date*: 2010-08-26
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: Open-label safety study of a 1-year 20 mg dose regimen of tasimelteon for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in blind individuals with no light perception.
    Medical condition: Non-24 Hour Sleep-Wake Disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013419 Disruptions of 24 hour sleep-wake cycle LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000120-17 Sponsor Protocol Number: APL-510-009 Start Date*: 2005-03-24
    Sponsor Name:Alliance Pharmaceuticals Ltd
    Full Title: A double-blind placebo-controlled cross-over study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of ...
    Medical condition: Transient misalignment of the sleep-wake cycle as a result of working night shifts (insomnia in night shift workers)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003203-32 Sponsor Protocol Number: 3115A1-3307-WW Start Date*: 2009-04-17
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OST...
    Medical condition: Menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027309 Menopause and related conditions HLGT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006788-11 Sponsor Protocol Number: NBI-827104-CSWS2025 Start Date*: 2022-03-25
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
    Medical condition: Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003141-11 Sponsor Protocol Number: NBI-827104-CSWS2010 Start Date*: 2021-09-03
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with E...
    Medical condition: Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000359-29 Sponsor Protocol Number: CLFT218-1501 Start Date*: 2016-11-09
    Sponsor Name:Flamel Ireland Limited (trading under the business name Avadel Ireland)
    Full Title: A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT...
    Medical condition: The treatment of cataplexy and excessive daytime sleepiness on narcolepsy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10007738 Cataplexy and narcolepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Prematurely Ended) DE (Completed) GB (Completed) FI (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003955-23 Sponsor Protocol Number: DR2 Start Date*: 2016-04-15
    Sponsor Name:Dept. of Ophthalmology, Rigshospitalet – Glostrup
    Full Title: Diabetic retinopathy: Effects of melatonin treatment on visual functions and circadian rhythm.
    Medical condition: Diabetic Retinopathy and Sleep disorder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023030-23 Sponsor Protocol Number: 10076 Start Date*: 2010-12-24
    Sponsor Name:The Univeristy of Nottingham [...]
    1. The Univeristy of Nottingham
    2.
    Full Title: Circadian Rhythm In Tobramycin Elimination in Cystic Fibrosis (CRITIC) - a Randomised Pharmacokinetic Comparison of Tobramycin in CF
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001688-31 Sponsor Protocol Number: 604296B Start Date*: 2007-06-04
    Sponsor Name:Larime company of the Mediscis group
    Full Title: Monitoring des états cognitifs chez des sujets volontaires sains, sur 2 périodes, l'une avant et après administration d'une dose unique de Zolpidem, l'autre sans administration de traitement
    Medical condition: It's a phase II study performed on healthy volonteers. Zolpidem (DCI) will be administered to the volunteers in order to inducing a drowsiness and a hypoattentiveness. Zolpidem is indicated in the ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022437 Insomnia LLT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004893-84 Sponsor Protocol Number: CBD-P Start Date*: 2019-08-22
    Sponsor Name:Mental Health Center Glostrup
    Full Title: Cannabidiol for treatment of non-affective psychosis and cannabis use
    Medical condition: Non-affective psychosis and lifetime cannabis use
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    21.1 100000004869 10070996 Cannabis use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003866-19 Sponsor Protocol Number: 83336 Start Date*: 2023-05-01
    Sponsor Name:Amsterdam UMC location AMC
    Full Title: The effect of low-dose rhythmic 17-β-estradiol administration on bone turnover in postmenopausal women
    Medical condition: Osteoporosis prevention
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003824-36 Sponsor Protocol Number: SATEME-08 Start Date*: 2005-09-15
    Sponsor Name:Fundació Institut Català de Farmacologia
    Full Title: Randomized, double blind, parallel groups, placebo controlled pivotal clinical trial to asses preliminary efficacy and security of a sublingual Cannabis Standardized Extract (Sativex) added to refe...
    Medical condition: Chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005383-42 Sponsor Protocol Number: BREATH Start Date*: 2016-05-19
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Use of buspiron in chemioreflex modulation and central apnea treatment in heart failure patients (BREATH: BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients)....
    Medical condition: patient with central apneas syndrome and heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10011949 Decompensation cardiac LLT
    20.0 100000004852 10040978 Sleep apnoeas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004516-22 Sponsor Protocol Number: 04-4025 Start Date*: 2005-02-01
    Sponsor Name:Uppsala University
    Full Title: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000567-77 Sponsor Protocol Number: 42847922MDD1016 Start Date*: 2021-05-19
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have ...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA ES (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000317-14 Sponsor Protocol Number: RAD-GRIN-101 Start Date*: 2022-11-28
    Sponsor Name:GRIN Therapeutics, Inc.
    Full Title: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-...
    Medical condition: gain of function (GoF) variants in the GRIN2B gene
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10064062 Neurodevelopmental disorder PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:23:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA